

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Lincoln Medical (Pitolisant hydrochloride) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> British Lung Foundation British Snoring and Sleep Apnoea Association Hope2Sleep Muslim Council of Britain Narcolepsy UK OSA Partnership Group Sleep Apnoea Trust South Asian Health Foundation Specialised Healthcare Alliance The Sleep Council <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association for Respiratory Technology & Physiology Association of Respiratory Nurse Specialists. British Geriatrics Society British Sleep Society British Society of Dental Sleep Medicine British Society of Rehabilitative Medicine British Thoracic Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Accord-UK Ltd (methylphenidate) Aurobindo Pharma - Milpharm Ltd. (modafinil) Flynn Pharma Ltd (dexamphetamine, methylphenidate) Generics UK T/A Mylan (methylphenidate) Janssen-Cilag Ltd (methylphenidate) Jazz Pharmaceuticals (solriamfetol) Martindale Pharma (dexamphetamine) Novartis Pharmaceuticals UK Ltd (methylphenidate)

Final stakeholder list for the proposed technology appraisal of pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea ID1065

Issue date: March 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Society of Medicine – Sleep medicine section • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS East Lancashire CCG • NHS England • NHS Hartlepool and Stockton-On-Tees CCG • Welsh Government 	<ul style="list-style-type: none"> • Sandoz Limited (methylphenidate) • Shire Pharmaceuticals Limited (methylphenidate) • Teva Pharma B.V (modafinil) • UCB Pharma Limited (sodium oxybate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Association for Lung Research • Cochrane Airways Group • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.